Pressure on Switzerland’s Medicine Supply: Pharmaceutical Sector Warns of Persistent Shortages Affecting More Than 700 Everyday Drugs
Switzerland is facing a prolonged medicine-supply squeeze. More than 700 medicines are currently affected by supply bottlenecks, according to drugshortage.ch, a monitoring platform created by hospital pharmacist Enea Martinelli. The figure refers to individual medicine packs and therefore does not mean that 700 different active ingredients are unavailable. Even so, it signals a problem that reaches far beyond an occasional empty shelf. 1
The disruption includes products used in everyday care as well as medicines needed in hospitals. An analysis of the platform identified 67 medicines containing 42 distinct active ingredients that were classified as facing critical or very critical shortages. Those ingredients included treatments for cancer, infections, eye conditions, blood disorders, neurological diseases, pain, heart disease, addiction treatment and psychiatric care. 1
A shortage that is wider than the official essential-medicines list
Switzerland’s federal monitoring system is designed primarily to identify shortages of essential human medicines. Since 2015, suppliers have had to notify the Federal Office for National Economic Supply when reportable medicines face supply interruptions. In January 2026, the list of reportable active substances was expanded to about 330. A new platform launched in 2025 is also intended to support proactive monitoring and an early-warning system. 2
That system is important, but it does not capture every product that patients may need. Drugshortage.ch tracks a broader range of packs, drawing information from pharmaceutical companies and a wholesaler serving healthcare providers. This difference in scope helps explain why the public count can be higher than the number recorded in the official essential-medicines system. 1 2
The distinction is especially relevant for people living with chronic conditions. A medicine may not be classified as essential under the narrowest emergency criteria, yet its absence can still force a patient to change treatment, visit several pharmacies or accept a less suitable substitute.
Why a wealthy pharmaceutical country is still exposed
The weakness is not caused by one failed factory. It reflects the structure of the global medicines market. Key active pharmaceutical ingredients and finished products are often manufactured by a small number of companies and production sites. Many stages of the value chain have moved to lower-cost locations in Asia, while just-in-time production has reduced the reserves held between manufacturers, wholesalers and pharmacies. 3
This concentration creates a chain reaction. A quality problem, shortage of raw materials, production delay, transport disruption, export restriction or sudden increase in demand can interrupt deliveries across several countries at once. Older generics, antibiotics, injectable cancer drugs and opioids are particularly exposed because they can have few suppliers and relatively low commercial margins. 1 3
Switzerland has additional vulnerabilities. Its domestic market is small by international standards, and manufacturers may be less willing to maintain several suppliers or prioritise Swiss deliveries when stocks are tight. The country also depends heavily on international production. The result is a paradox: Switzerland is a major pharmaceutical centre, yet its local patients can remain dependent on decisions made elsewhere in the supply chain. 3
What pharmacies and authorities can do when stock runs out
Switzerland has several emergency mechanisms. Compulsory reserves can cover two to four months of market demand, depending on the product, and the country maintains larger strategic stocks for selected essential medicines. When an authorised medicine is unavailable, Swissmedic can approve the temporary sale of an identical product in packaging intended for another country, provided the product is therapeutically important, safe and has no adequate Swiss alternative. 2 4
Pharmacies and hospital pharmacies may also prepare medicines or provide a substitute treatment under exceptional rules. Since 2023, measures have included reimbursement for medicines prepared by pharmacies and the possibility of selling smaller quantities of certain products. These tools can reduce immediate harm, but they do not create new manufacturing capacity. 3
A stockpile can buy time. It cannot permanently solve a market with too few producers, weak incentives and limited visibility outside the essential-medicines category. When a product is unavailable for months, pharmacists spend time locating alternatives, clinicians adjust prescriptions and patients carry the uncertainty.
The political response is moving, but slowly
The popular initiative “Yes to the Security of Medical Care” seeks a stronger federal role in securing medicines and other medical products. The National Council has recommended rejecting the initiative while supporting a direct counter-proposal from the Federal Council. Five of the six parliamentary groups agreed that the underlying problem is real, although most preferred the government’s more targeted approach. The measures now move to the Council of States. 1
The federal government has also been developing a broader framework. By the end of 2026, Switzerland plans to classify all authorised medicines into categories so that availability can be monitored beyond the current essential-products list. The government has also considered easier imports from the European Union and the use of QR codes instead of Swiss-specific multilingual leaflets in some circumstances, which could make it simpler to bring equivalent products to market during a disruption. 3
The pharmaceutical sector argues that supply security must also be connected to the competitiveness of Switzerland as a production and life-sciences location. Interpharma says Switzerland generates almost seven percent of global pharmaceutical value creation while representing only about 0.6 percent of the global market. It warns that trade policies, regional-production strategies and regulatory decisions could affect both investment and patient access. 5
That argument deserves careful scrutiny. Innovation policy and supply policy overlap, but they are not identical. A country can host high-value research and still lack reliable access to low-margin generics. Resilience may require separate incentives for products that are clinically important but commercially unattractive, including stronger purchasing commitments, diversified suppliers, transparent shortage data and carefully designed reserve requirements.
Closing Thoughts
The central lesson is that medicine availability cannot be judged only by the strength of a country’s pharmaceutical exports. Switzerland can be a global centre for research and high-value production while remaining vulnerable to shortages of ordinary antibiotics, painkillers, insulin or hospital medicines.
The current figure of more than 700 affected products should be treated as a warning about visibility and resilience, not simply as a headline number. The most useful response is likely to combine better data, earlier warnings, targeted reserves, faster access to equivalent products and economic conditions that keep several suppliers in the market. Patients need a system that anticipates disruption rather than one that reacts after the pharmacy shelf is empty.
What is the true implication of this?
The true implication is a shift in risk. A shortage is no longer only a logistical inconvenience; it can become a clinical decision. Doctors may need to change a treatment, pharmacists may need to prepare or source an alternative, and patients may face delays in care. If shortages remain concentrated in older generics and essential hospital products, the pressure will fall most heavily on treatments that health systems depend on every day but that often receive the least commercial attention.
What makes this significant?
This is significant because it tests the assumption that wealth, regulation and a strong pharmaceutical reputation automatically guarantee access. Switzerland’s experience shows that access depends on the full chain: raw materials, manufacturing capacity, transport, national purchasing rules, reserves, market incentives and timely information. The policy choices made now will determine whether the country treats recurring shortages as isolated incidents or builds a more dependable supply system.
References
Comments